Cellectis S.A. Company Name:
CLLS Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin Lymphoma Cellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in May Mr. Axel-Sven Malkomes & Dr. Donal...
UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house Phase 1/2a clinical trial NatHaLi-01 expected to be...
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the seco...